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Objectives. We sought to evaluate the current evidence for an
effect of beta-blockade treatment on mortality in patients with
congestive heart failure (CHF).
Background. Although numerous small studies have suggested
a benefit with beta-blocker therapy in patients with heart failure,
a clear survival benefit has not been demonstrated. A recent
combined analysis of several studies with the alpha- and beta-
adrenergic blocking agent carvedilol demonstrated a significant
survival advantage; however, the total number of events was small.
Furthermore, it is unclear if previous studies with other beta-
blockers are consistent with this finding.
Methods. Randomized clinical trials of beta-blockade treat-
ment in patients with CHF from January 1975 through February
1997 were identified using a MEDLINE search and a review of
reports from scientific meetings. Studies were included if mortal-
ity was reported during 3 or more months of follow-up.
Results. We identified 35 reports, 17 of which met the inclusion
criteria. These studies included 3,039 patients with follow-up
ranging from 3 months to 2 years. Beta-blockade was associated
with a trend toward mortality reduction in 13 studies. When all 17
reports were combined, beta-blockade significantly reduced all-
cause mortality (random effect odds ratio [OR] 0.69, 95% confi-
dence interval [CI] 0.54 to 0.88). A trend toward greater treatment
effect was noted for nonsudden cardiac death (OR 0.58, 95% CI
0.40 to 0.83) compared with sudden cardiac death (OR 0.84, 95%
CI 0.59 to 1.2). Similar reductions in mortality were observed for
patients with ischemic (OR 0.69, 95% CI 0.49 to 0.98) and
nonischemic cardiomyopathy (OR 0.69, 95% CI 0.47 to 0.99). The
survival benefit was greater for trials of the drug carvedilol (OR
0.54, 95% CI 0.36 to 0.81) than for noncarvedilol drugs (OR 0.82,
95% CI 0.60 to 1.12); however, the difference did not reach
statistical significance (p 5 0.10).
Conclusions. Pooled evidence suggests that beta-blockade re-
duces all-cause mortality in patients with CHF. Additional trials
are required to determine whether carvedilol differs in its effect
from other agents.
(J Am Coll Cardiol 1997;30:27–34)
©1997 by the American College of Cardiology
Congestive heart failure (CHF) is listed as the primary cause of
death for 40,000 patients annually, and this number has
increased dramatically over the past decade (1,2). It is esti-
mated that more than 4 million Americans are affected with
heart failure, and that more than 400,000 new cases occur each
year (1).
Because angiotensin-converting enzyme (ACE) inhibitors
have significantly reduced mortality rates, they have become a
standard therapy for virtually all patients with CHF due to left
ventricular systolic dysfunction (3–5). Whether other agents
used in the treatment of heart failure have a similar survival
benefit remains unclear. The combination vasodilator regimen
of hydralazine plus isosorbide dinitrate significantly prolonged
survival in the first Veteran Affairs Heart Failure Trial (V-
HeFT) (6), but to a lesser degree than an angiotensin-
converting enzyme inhibitor in V-HeFT II (5), and there are
no data to indicate that these approaches have additive benefit.
The recently completed Digitalis Investigation Group trial
showed no overall reduction (or increase) in mortality with
digoxin (7). Several other treatments, such as amiodarone
(8,9), amlodipine (10) and vesnarinone (11) have been associ-
ated with nonconclusive or adverse results, with the possibility
of benefit in a subset of patients.
Although seemingly counterintuitive, beta-adrenergic block-
ing agents have been advocated as a treatment for CHF for more
than two decades, with a postulated action of mitigating the
potentially deleterious effects of sympathetic nervous system
hyperactivity (12,13). Interest in this approach has grown in
recent years as an increasing number of small- and medium-sized
studies have shown improvements in left ventricular ejection
fraction, symptoms and morbidity indices (14–21). Recently, a
summary report of four randomized trials of the combined beta-
and alpha-adrenergic blocking agent carvedilol demonstrated a
survival advantage in patients with heart failure (22). However, a
number of important issues remain unresolved (23).
This meta-analysis was undertaken to address the following:
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1) Is there evidence for a mortality benefit when beta-blockade
is added to standard therapy in patients with heart failure? 2)
Is the substantial benefit recently reported with carvedilol (22)
consistent with or greater than that observed with other
beta-blockers? 3) Is the benefit, if confirmed, attributable to a
reduction in sudden deaths and in deaths due to progressive
heart failure? 4) Does the benefit present in patients with heart
failure extend to both ischemic and nonischemic causes?
Methods
Data identification. We attempted to identify all random-
ized trials of beta-blockade in patients with chronic CHF.
Candidate trials were sought through a computerized biblio-
graphic search of the MEDLINE data base (National Library
of Medicine, Bethesda, Maryland) for the period January 1975
to February 1997, and were required to include randomization
in their design. The reference lists of all articles obtained were
examined to identify additional studies. Abstracted studies
from presentations at national meetings were included if they
met the design criteria.
Research selection. All titles and abstracts from the search
process were examined. Studies were retrieved if they met the
following criteria: 1) randomized comparison of a beta-blocker
with a placebo control; 2) study duration $3 months; 3) all
study subjects had a history of CHF; and 4) the study drug was
a beta-blocker without intrinsic sympathomimetic activity.
The retrieved studies were examined and included in the
final set if: 1) mortality was reported and could be separated
into control and active drug deaths on the basis of intention to
treat; and 2) no drug crossovers were planned before the
reporting of mortality.
Two reviewers (P.A.H. and T.T.L.) abstracted data from
each study independently. These data included age, gender,
mean ejection fraction, New York Heart Association func-
tional class, ischemic or nonischemic etiology of heart failure,
concomitant use of ACE inhibitors, mean follow-up time,
study withdrawals, hospital admissions, total mortality, cardiac
mortality and sudden death mortality. Total mortality was the
major end point of interest.
We programmed a spreadsheet (Excel, Microsoft Corp.) to
combine all outcomes. We pooled data using averages of effect
weighted by the inverse of the variance (24). For studies with
no deaths in the drug or control arms, the value 0.5 was used
in place of 0 deaths for calculations (see Appendix). The
summary odds ratio (OR) was calculated for both the Mantel-
Haenszel fixed effects (25–27) and the DerSimonian and Laird
random effects methods (28,29). A test of homogeneity (30)
and summary rate-difference (24) were also calculated. Differ-
ences between subgroups were evaluated using analysis of
variance as described by Hedges and Olkin (31,32). Random
effects ORs with 95% confidence intervals (CIs) are reported
unless otherwise stated. All reported p values are two-tailed
with statistical significance at p , 0.05.
Results
Pooling of trials. We identified 35 published reports of
randomized trials of beta-blockade in patients with heart
failure (14–20,33–60). Eighteen studies (16,20,45–61) were
excluded for the following reasons: in six, the study time was
,3 months (46–48,50,52,53); in five, the trial was a substudy of
a larger reported trial in which the same patients and deaths
were included (45,49,56,58,59); in three, mortality was not
reported (16,20,54); and in four, there was no placebo control
(51,55,57,60).
The 17 trials used in our analysis (Tables 1 and 2) included
a total of 3,039 patients (1,723 randomized to beta-blockade
and 1,316 randomized to control) (14,15,17–19,33–44). We
included data from the recent evaluation of carvedilol (report-
ed as one study by Packer et al. [22]) by treating the four
component studies (34–37) separately in the evaluation of
all-cause mortality. Because this report accounted for 18% of
the deaths and 36% of the patients, we performed all analyses
both with and without the data from this report.
Total mortality. The 17 studies accounted for 293 deaths
during a mean 8.9 6 7 months of follow-up. The majority of
these were cardiac deaths (n 5 247, 84% of all deaths), and
half of these were classified as sudden (n 5 120, 49% of cardiac
deaths). The mean mortality rate adjusted for trial size was
11% per year. A trend toward mortality reduction with beta-
blockade was noted in 13 studies, but only one reached
statistical significance (Table 2, Fig. 1). After combining the 17
trials, beta-blockade treatment was associated with a signifi-
cant reduction in mortality with a summary OR of 0.69 (95%
CI 0.54 to 0.88). A similar summary OR of 0.70 (95% CI 0.54
to 0.89) was obtained when the data from the four recent
carvedilol trials (34–37) were included as one study (22). The
summary or rate-difference between the control and treatment
arms in the 17 studies was 2.9 (95% CI 1.2 to 4.6) deaths/100
patients treated. This value suggests that one death can be
prevented for 35 (95% CI 22 to 84) patients treated over a
period of 9 months. The chi-square test for homogeneity
revealed that differences in the effect of beta-blockade between
studies could be explained by chance alone (p 5 0.9).
Deaths occurred during initial open-label phases of three
trials of carvedilol (19,22,62). The reports did not include these
deaths in the mortality statistics. It is possible that beta-
blockade treatment contributed to the deaths, and the re-
ported mortality benefits are therefore overestimated. To
address this we performed a separate analysis by including all
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BEST 5 Beta-Blocker Evaluation of Survival Trial
CHF 5 congestive heart failure
CI 5 confidence interval
OR 5 odds ratio
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open label deaths as beta-blockade deaths. This minimally
increased the summary OR (and decreased the mortality
benefit) for beta-blockade to 0.75 (95% CI 0.59 to 0.96) from
0.69 (95% CI 0.54 to 0.88). The number needed to treat to
prevent one death also increased to 41 (95% CI 23 to 179)
from 35 (95% CI 22 to 84).
Table 1. Randomized Trials of Beta-Blockade in Patients With Congestive Heart Failure: Study Characteristics
Study (ref. no.)
Beta-
Blocker
Mean FU
(mo)
Mean Age
(yr)
%
Male
Mean
LVEF (%)
NYHA Class (%)
ACE
Inhibitor (%)
Primary
End Point
Open Label
Deaths (%)I II III IV
Anderson et al. (14) Metoprolol 19 50 66 28 Mean class 2.8 NS Mortality NA
Australia/New Zealand (39) Carvedilol 19 67 80 29 30 54 16 0 86 LV func 3 (0.7%)*
Bristow et al. (15) Bucindolol 3 55 61 24 1 42 56 1 88 LV func 0
CIBIS (33) Bisoprolol 23 60 83 25 0 0 95 5 90 Mortality NA
Engelmeier et al. (17) Metoprolol 10 50 64 17 0 40 46 14 NS† LV func 0
Fisher et al. (18) Metoprolol 6 63 96 23 0 40 46 14 94 LV func NA
Krum et al. (19) Carvedilol 3 55 78 16 0 27 63 10 90 LV func 4 (7%)
MDC (44) Metoprolol 15 49 72 22 2 44 49 4 80 Mortality 0
Metra et al. (41) Carvedilol 4 51 90 20 0 28 72 0 98 LV func NA
Olsen et al. (40) Carvedilol 4 52 93 20 0 50 50 0 93 Symptoms 0
Packer et al. (22)‡ Carvedilol 6.5 58 77 23 0 53 44 3 95 Mortality 7 (0.6%)
Colucci et al. (36) Carvedilol 7 54 85 23 0 85 15 0 98 Symptoms 1 (0.3%)
PRECISE (37) Carvedilol 6 60 73 22 0 40 56 4 97 Ex tol 5 (1.7%)
Bristow et al. (35) Carvedilol 5.5 63 76 23 0 46 52 2 94 Ex tol 1 (0.3%)
Carvedilol efficacy (34) Carvedilol NS§ NS NS NS NS NS NS NS NS NS NS
Pollock et al. (38) Bucindolol 3 54 79 21 0 5 74 21 NS\ LV func 0
Wisenbaugh et al. (43) Nebivolol 3 50 50 24 0 96 4 0 0 LV func NA
Woodley et al. (42) Bucindolol 3 52 72 22 Mean class 2.6 76 LV func 0
*Data taken from initial 1995 report (58). †Forty percent of patients were taking vasodilators. ‡This summary report is included for reference; the four component
studies were included separately for total mortality analysis. §Descriptive data not published as of this writing but included in the summary report (22). \Seventy-nine
percent of patients were taking vasodilators. ACE 5 angiotensin-converting enzyme; CIBIS 5 Cardiac Insufficiency Bisoprolol Study; LVEF 5 ejection fraction; LV
func 5 left ventricular function; MDC 5 Metoprolol in Dilated Cardiomyopathy trial; NA 5 not applicable; NS 5 not stated; NYHA class 5 New York Heart
Association functional class; PRECISE 5 Prospective Randomized Evaluation of Carvedilol in Symptoms and Exercise; ref. 5 reference.
Table 2. Randomized Trials of Beta-Blockade in Patients With Congestive Heart Failure: Effect of
Beta-Blockade on Mortality
Study (ref. no.)
Deaths/Sample Size OR (95% CI)*
Beta-Blocker Control Total Death Cardiac Death Sudden Death
Anderson et al. (14) 5/25 6/25 0.79 (0.21–3.0) 0.79 (0.21–3.0) 0.31 (0.03–3.0)
Australia/New Zealand (39) 20/207 26/208 0.75 (0.40–1.4) 0.90 (0.46–1.8) 0.91 (0.38–2.2)
Bristow et al. (15) 4/105 2/34 0.63 (0.11–3.6) 0.63 (0.11–3.6) 0.63 (0.11–3.6)
CIBIS (33) 53/320 67/321 0.75 (0.50–1.1) 0.63 (0.41–0.98) 0.88 (0.43–1.8)
Engelmeier et al. (17) 1/9 2/16 0.88 (0.07–11) 0.88 (0.07–11) 0.88 (0.03–29)
Fisher et al. (18) 1/25 2/25 0.48 (0.04–5.7) 0.23 (0.01–5.5) 1.00 (0.02–52)
Krum et al. (19) 3/33 2/16 0.70 (0.10–4.6) 0.98 (0.08–11) 0.97 (0.08–12)
MDC (44) 23/194 21/189 1.08 (0.57–2.0) 1.36 (0.70–2.6) 1.51 (0.71–3.2)
Metra et al. (41) 0/20 0/20 1.00 (0.02–53) 1.00 (0.02–53) 1.00 (0.02–53)
Olsen et al. (40) 1/36 0/24 1.34 (0.04–42) 1.34 (0.04–42) 1.34 (0.04–42)
Packer (22)† 22/696 31/398 0.39 (0.22–0.68) 0.35 (0.20–0.62) 0.45 (0.21–0.97)
Colucci et al. (36) 2/232 5/134 0.22 (0.04–1.2) NA‡ 0.14 (0.01–3.2)
PRECISE (37) 6/133 11/145 0.58 (0.21–1.6) NA NA
Bristow et al. (35) 12/261 13/84 0.26 (0.12–0.60) 0.2 (0.08–0.47) 0.31 (0.10–0.98)
Carvedilol efficacy (34) 2/70 2/35 0.49 (0.07–3.6) NA NA
Pollock et al. (38) 0/12 0/7 0.57 (0.01–32) 0.57 (0.01–32) 0.57 (0.01–32)
Wisenbaugh et al. (43) 1/11 0/13 2.5 (0.08–82) 2.5 (0.08–82) 2.5 (0.08–82)
Woodley et al. (42) 0/30 0/20 0.66 (0.01–35) 0.66 (0.01–35) 0.66 (0.01–35)
Total 134/1,723 159/1,316 0.69 (0.54–0.88) 0.68 (0.53–0.89) 0.84 (0.59–1.2)
*We used 0.5 in place of 0 deaths for odds ratio calculations. †Summary study given as a reference. The summary
odds ratio for total mortality was calculated using the data as four separate studies. When the one summary study is used
in place of the four separate studies, the summary odds ratio remains similar (0.70, 95% CI 0.54–0.89). ‡Separate data
for cardiac death and sudden death were not available for some studies. CI 5 confidence interval; OR 5 odds ratio; other
abbreviations as in Table 1.
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Cardiac and sudden death mortality. Beta-blockade was
associated with a similar reduction in cardiac mortality (Table
2): summary OR 0.68 (95% CI 0.53 to 0.89). The summary
rate-difference was 3.0 (95% CI 1.0 to 4.8) fewer deaths per
100 patients. This corresponds to one cardiac death prevented
for every 33 (95% CI 21 to 82) patients treated.
A majority of trials demonstrated an association between
beta-blockade treatment and a reduction in sudden cardiac
death (Table 2). The summary OR 0.84 (95% CI 0.59 to 1.2)
did not reach statistical significance. This is in contrast to
nonsudden cardiac death, for which the summary OR was
highly significant 0.58 (95% CI 0.40 to 0.83).
Ischemic versus nonischemic cardiomyopathy. Separate
data were available for ischemic cardiomyopathy in seven trials
including 1,387 patients (Table 3) (18,22,33,38–40,42) and for
nonischemic cardiomyopathy in nine trials including 1,436
patients (Table 4) (14,17,22,33,38,40–42,44). There were no
significant differences in the summary OR between the two
groups: ischemic OR 0.69 (95% CI 0.49 to 0.98), nonischemic
OR 0.69 (95% CI 0.47 to 0.99).
Carvedilol versus other beta-blockers. We compared the
differences in survival benefit between carvedilol and non-
carvedilol trials (Table 5). Only the carvedilol trials, when
pooled, demonstrated a significant survival benefit. The carve-
Figure 1. ORs and 95% CIs for
effect of beta-blockade on total
mortality for the 17 studies in-
cluded in the meta-analysis. The
summary OR estimate is 0.69
(95% CI 0.54 to 0.88). CIBIS 5
Cardiac Insufficiency Bisoprolol
Study; MDC 5 Metoprolol in
Dilated Cardiomyopathy trial;
PRECISE 5 Prospective Ran-
domized Evaluation of Carve-
dilol in Symptoms and Exercise.
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dilol trials also were associated with a greater reduction in
cardiac death (OR 0.44 [95% CI 0.28 to 0.69]) compared with
the noncarvedilol trials (OR 0.79 [95% CI 0.56 to 1.10]) (p 5
0.04). However, the difference in ORs for total mortality
between carvedilol and noncarvedilol trials was not statistically
significant (p 5 0.11).
The reduction in mortality was more pronounced for non-
sudden than sudden cardiac death in both carvedilol and
noncarvedilol trials. The carvedilol trials were associated with
a greater sudden death survival benefit (OR 0.51 [95% CI 0.28
to 0.92]) compared with the noncarvedilol trials (OR 1.03
[95% CI 0.65 to 1.66]) (p 5 0.04). The differences for
nonsudden cardiac death for the carvedilol trials (OR 0.39
[95% CI 0.20 to 0.75]) compared with the noncarvedilol trials
(OR 0.66 [95% CI 0.42 to 1.02]) was not significant (p 5 0.19).
We examined the effect of beta-blockade in patient sub-
groups by grouping the trials according to several patient
characteristics (Table 5). All subgroups of studies demon-
strated an association between beta-blockade and improved
survival (summary OR ,1.0).
In-hospital data. In-hospital data for drug and placebo
groups were available from eight studies (17,18,33,35–
37,43,44). A total of 200 of 915 patients treated with placebo
were admitted compared with 142 of 1,175 patients treated
with beta-blockers. The summary OR was 0.59 (95% CI 0.47 to
0.76), demonstrating a significant reduction in hospital stays
for patients treated with beta-blockers. When trials of carve-
dilol were compared with other beta-blocker trials, there was
no obvious difference in the decrease in hospital admissions:
OR 0.60 (95% CI 0.45 to 0.8) for trials of noncarvedilol
beta-blockers versus placebo, and OR 0.58 (95% CI 0.37 to
0.91) for trials of carvedilol versus placebo.
Impact of ongoing investigations. We examined the poten-
tial impact of several hypothetic results of the ongoing Beta-
Blocker Evaluation of Survival Trial (BEST) (63) on the
summary OR (Fig. 2). For BEST to eliminate the favorable
OR from previous studies (i.e., resulting in a summary OR of
1.0), an OR of 1.25 (25% increase in the odds of death) would
be required. To eliminate a statistical significance in the
summary OR (95% CIs include 1.0), an OR of 0.98 would need
to be observed with BEST.
Discussion
This analysis demonstrates that trial results of beta-blocker
therapy in patients with CHF are consistent with a beneficial
effect on total and cardiovascular mortality. The overall de-
crease in the odds of death was 31%, with one death prevented
Table 3. Randomized Trials of Beta-Blockade in Patients With
Ischemic Cardiomyopathy: Effect of Beta-Blockade on Mortality
Study (ref. no.)
Deaths/Sample Size
Total Death
[OR (95% CI)]*Beta-Blocker Control
Australia/New Zealand (39) 20/207 26/208 0.75 (0.40–1.4)
CIBIS (33) 36/180 38/170 0.87 (0.52–1.5)
Fisher et al. (18) 1/25 2/25 0.48 (0.04–5.7)
Olsen et al. (40) 1/13 0/4 0.58 (0.02–21)
Packer et al. (22)† 13/332 17/189 0.41 (0.20–0.87)
Pollock et al. (38) 0/5 0/2 0.33 (0.00–25)
Woodley et al. (42) 0/16 0/11 0.68 (0.01–37)
Total 71/778 83/609 0.69 (0.49–0.98)
*We used 0.5 in place of 0 deaths for odds ratio calculations. †Data from the
summary trial were used because data were unavailable for three of four of the
component trials. Abbreviations as in Tables 1 and 2.
Table 4. Randomized Trials of Beta-Blockade in Patients With
Nonischemic Cardiomyopathy: Effect of Beta-Blockade on Mortality
Study (ref. no.)
Deaths/Sample Size Total Death
[OR (95%
CI)]*Beta-Blocker Control
Anderson et al. (14) 5/25 6/25 0.79 (0.21–3.0)
CIBIS (33) 17/140 29/151 0.58 (0.30–1.1)
Engelmeier et al. (17) 1/9 2/16 0.88 (0.07–11)
MDC (44) 23/194 21/189 1.08 (0.57–2.0)
Metra et al. (41) 0/20 0/20 1.00 (0.02–53)
Olsen et al. (40) 0/23 0/20 0.87 (0.02–46)
Packer et al. (22)† 9/362 14/208 0.35 (0.15–0.83)
Pollock et al. (38) 0/7 0/5 0.69 (0.01–42)
Woodley et al. (42) 0/13 0/9 0.68 (0.01–38)
Total 55/793 72/643 0.69 (0.47–0.99)
*We used 0.5 in place of 0 deaths for odds ratio calculations. †Data from the
summary trial were used because data were unavailable for three of four of the
component trials. Abbreviations as in Tables 1 and 2.
Table 5. Subgroup Differences of the Effect of Beta-Blockade on
Total Mortality
Study Subgroup Trials*
Deaths/Sample Size
Summary OR
(95% CI)
p
ValueBeta-Blocker Control
Carvedilol 8 46/992 59/666 0.54 (0.36–0.81) 0.11
Other beta-blocker 9 88/731 100/650 0.82 (0.60–1.12)
LVEF #22% 7 67/666 84/581 0.72 (0.5–1.02) 0.9
LVEF .22% 9 61/987 67/700 0.74 (0.52–1.08)
Age ,60 yr 11 40/707 38/498 0.85 (0.53–1.36) 0.4
Age $60 yr 5 88/946 113/783 0.68 (0.51–0.93)
Mortality end point 3 81/539 94/535 0.83 (0.60–1.15) 0.2
Other end point 13 47/1,114 57/746 0.60 (0.40–0.90)
ACE inhibitor ,50% 3 7/45 8/54 0.91 (0.30–2.8) 0.7
ACE inhibitor $50% 13 121/1,608 143/1,227 0.72 (0.56–0.94)
Follow-up $9 mo 5 102/755 122/759 0.81 (0.61–1.08) 0.11
Follow-up ,9 mo 12 26/898 29/522 0.49 (0.29–0.85)
NYHA class #2.5 5 25/495 33/395 0.69 (0.40–1.20) 0.8
NYHA class .2.5 11 103/1,158 118/886 0.74 (0.56–0.99)
$75% male 9 40/507 42/442 0.67 (0.50–0.91) 0.3
,75% male 7 88/1,146 109/839 0.88 (0.58–1.65)
*Descriptive data were incomplete for one trial of carvedilol (34). Abbrevi-
ations as in Tables 1 and 2.
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per 35 patients treated. The benefit from beta-blockade was
consistent over the studies examined; however, it was most
pronounced in the studies of carvedilol, which account for 55%
of all included patients.
Previous studies, including a meta-analysis (21), have dem-
onstrated that beta-blockade can improve left ventricular
ejection fraction, symptoms and morbidity indices (14–20).
The finding of improved mortality with beta-blockade has also
been suggested by many previous studies, but most have lacked
the statistical power to find even moderate improvements in
survival (14,15,17,18,33,38,42–44,49,56). The results from this
meta-analysis increase confidence in the hypothesis that beta-
blockade reduces mortality in heart failure.
Previous studies have suggested that patients with ischemic
and nonischemic cardiomyopathies may respond differently to
beta-blockade therapy (33), as well as to other therapies for
heart failure such as amlodipine (10), amiodarone (64) and
digoxin (7). We found that the etiology of heart failure did not
affect the response to beta-blockade therapy.
The mechanism of improved survival with beta-blockade
treatment remains unclear (65,66). The reduction in nonsud-
den cardiac death (42% decrease in the odds of death) was
more marked than the reduction in sudden death (16%
decrease). This difference was most notable in the noncarve-
dilol trials, which demonstrated a difference in sudden (4%
increase in the odds of death) compared with nonsudden
cardiac death (34% decrease in the odds of death). This
suggests that beta-blockade is more likely to prevent or delay
the progression of CHF than exert a primary antiarrhythmic
effect.
This study also addressed the question of heterogeneity in
mortality effects of different beta-blockers. Studies of the
beta-blocker carvedilol demonstrated a nonsignificant trend
toward improved survival compared with trials of other beta-
blockers. This was primarily an effect of the four carvedilol
trials recently summarized by Packer et al. (22), which dem-
onstrated a 65% decrease in the risk of death. Without these
trials the summary OR for carvedilol trials is 0.76 (95% CI 0.43
to 1.35), a value similar to the summary OR of 0.82 for all
noncarvedilol trials. With regard to sudden death, the im-
provement with carvedilol did reach statistical significance, but
the differentiation of mode of death is difficult, and cross-study
differences in sudden death criteria make it difficult to draw
firm conclusions.
Study limitations. As with any meta-analysis, this study
may be subject to publication bias—that is, a tendency not to
submit or publish studies demonstrating nonsignificant differ-
ences in therapy. However, we believe that a large randomized
trial of beta-blockade would be published in today’s academic
climate regardless of the results. All of the included studies
enrolled predominately clinically stable patients and very few
patients with severe heart failure. The majority of studies had
follow-up periods #12 months; thus, the long-term effect of
beta-blockade on survival is less clear. Distinguishing between
sudden and nonsudden cardiac death may be difficult, and our
findings are therefore limited by the accuracy of each trial’s
classification.
Conclusions. The aggregate of randomized controlled tri-
als suggests that beta-blockade results in a significant improve-
ment in survival for patients with heart failure. This improve-
ment appears greatest for nonsudden cardiac death, with the
use of the beta- and alpha-blocker carvedilol, and is unrelated
to the etiology of heart failure. Additional trials are required to
determine whether carvedilol differs in its effect from other
agents.
Appendix
Odds Ratio Calculation
To calculate odds ratios (ORs) in trials with zero deaths in one or
both study arms, we used a value of 0.5 deaths in place of 0. We also
tested values ranging from 0.01 to 1.0 death in place of 0. The summary
ORs were insensitive to this manipulation. For example, the total
mortality summary OR using 0.01 death in place of 0 deaths was 0.68
(95% confidence interval [CI] 0.53 to 0.88). This was similar to the OR
of 0.69 (95% CI 0.54 to 0.88) when 1.0 death was used in place of 0
deaths.
We thank Ingram Olkin, PhD, who conducted a seminar series on meta-analysis
at Stanford University during January to March 1996, where an earlier version of
this study was presented.
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